Thomas Malley

President at Mossrock Capital LLC

Thomas Malley

Thomas Malley

President at Mossrock Capital LLC

Overview
Career Highlights

Mossrock Capital LLC

RelSci Relationships

533

Number of Boards

6

Birthday

1969

Age

51

Contact Data
Trying to get in touch with Thomas Malley? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Thomas Malley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & Chairman of the Board at Kiniksa Pharmaceuticals Ltd.

Relationship likelihood: Strong

Co-Founder at Kura Oncology, Inc.

Relationship likelihood: Strong

Former Partner at Baker Bros. Advisors LP

Relationship likelihood: Strong

Founder at Puma Biotechnology, Inc.

Relationship likelihood: Strong

Co-Founder at Baker Bros. Advisors LP

Relationship likelihood: Strong

Co-Founder at BeiGene Ltd.

Relationship likelihood: Strong

Co-Founder at BeiGene Ltd.

Relationship likelihood: Strong

Founder at Project Cure, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Project Cure, Inc.

Relationship likelihood: Strong

Managing Director at General Atlantic Service Co. LP

Relationship likelihood: Strong

In The News
Paths to Thomas Malley
Potential Connections via
Relationship Science
You
Thomas Malley
President at Mossrock Capital LLC
Family Members
Spouse
Education
BS in Biology
Class of 1991
Career History
President
2007 - Current
Executive Vice President
1999 - 2007

JCM seeks to add value versus benchmarks by actively pursuing alpha generation through their own intensive fundamental research for their fundamental investment strategies. They look for companies possessing the firm’s key investment criteria through proprietary research that emphasizes contact with a company’s management team, competitors, suppliers and consumers, as well as in-depth and ongoing financial modeling. Holdings are generally selected one at a time with all other factors (industry, sector, country and cash allocations) being a residual of the investment process. JCM favors businesses that their research reveals have sustainable, above-average earnings growth potential and outstanding free cash flow generation, recurring revenue, profit margins and return on invested capital for their equity strategies. To build a mosaic of information in an effort to identify macro trends and inform allocations across fixed income sectors, the firm uses fundamental credit research.

Equity Analyst
1991 - 1998
Boards & Committees
Member, Board of Directors
2016 - Current
Independent Director
2016 - Current
Member, Board of Directors
2015 - Current
Member, Board of Directors
Current
Chair, Board of Directors
2007 - 2013
Investments
Details Hidden

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Thomas Malley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Thomas Malley's profile does not indicate a business or promotional relationship of any kind between RelSci and Thomas Malley.